CDK12 inactivation defines a new class of prostate cancer

6/15/2018

MCTP researchers, led by Yi-Mi Wu and Dan Robinson, have identified a new subtype of prostate cancer that occurs in about 7 percent of patients with advanced disease. The subtype is characterized by loss of the gene CDK12. It was found to be more common in metastatic prostate cancer compared with early stage tumors that had not spread. CDK12 mutant cases are associated with elevated neoantigen burden ensuing from fusion-induced chimeric open reading frames and increased tumor T cell infiltration/clonal expansion and thereby defines a distinct class of metastatic prostate cancers that may benefit from immune checkpoint immunotherapy.

Read more

Source: http://mctp.med.umich.edu/news/newsitem?nid=40